Department of Anesthesiology, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing, China. Electronic address: njfyjiangming@njmu.edu.cn.
2 papers in the library · 66 citations · publishing 2024-2025
A single low dose of esketamine given after childbirth reduces the risk of a major depressive episode at 42 days postpartum by about three quarters in mothers with prenatal depression. In a randomized trial of 364 mothers with at least mild prenatal depression, 6.7% of those receiving esketamine experienced a major depressive episode compared with 25.4% in the placebo group. Depression scores were also lower in the esketamine group at 7 and 42 days. Neuropsychiatric side effects were more common with esketamine (45.1% vs 22.0%) but were transient and resolved without drug treatment.
Prenatal chronic restraint stress (CRS) in mice induced postpartum depression-like behaviors in mothers and sex-specific behavioral changes in their adolescent offspring: female offspring showed depression-like behaviors, while male offspring exhibited memory deficits. Esketamine, given to mothers on postpartum days 1-5, improved these maternal depression-like behaviors and also corrected the behavioral abnormalities in adolescent offspring. Additionally, prenatal CRS caused heightened secretion of ACTH and CORT in adolescent offspring during acute restraint stress, indicating hyperresponsiveness of the stress hormone system. Esketamine's effects on these hormone levels were not reported.